Shares surged 14.6% to $1.49 as Cabaletta Bio unveiled clinical trial results at a major rheumatology conference over the weekend, delivering the kind of clean data that investors in battered small-cap biotechs rarely see — yet the stock still sits 65% below its 52-week high of $4.23, reflecting deep skepticism about whether the science can translate into an approved product before the money runs out.
Every Patient Responded, but the Sample Size Is Tiny. All six dermatomyositis patients maintained meaningful improvement scores through one year without needing other immune-suppressing drugs.
Separately, five of five biopsied lupus nephritis patients reached remission off immune-modulating drugs. Those are eye-catching hit rates, but a handful of patients in an open-label study — where both doctors and patients know what treatment they're getting — is far from proof. The data cut across 71 total patients treated with the therapy. Investors buying today are betting these small signals hold up in larger, more rigorous trials.
The Enrollment Slowdown Is the Real Risk. Cabaletta's CEO acknowledged that patient and physician caution slowed Q3 enrollment in the registrational myositis study — the pivotal trial needed for a U.S. approval application. The myositis application slipped to the first quarter of 2028 after competitor CAR-T deaths raised safety concerns across the field. Any further delays compress the window between spending and potential revenue. The company expects topline myositis results in the second half of 2027, with its approval application planned for the first quarter of 2028.
$299 Million in Cash Sounds Comfortable — Until You Do the Math. As of September 30, Cabaletta held approximately $299.4 million in cash, which management says funds operations into the first quarter of 2028.
But each quarter burns roughly $55 million in operating expenses. That runway ends almost exactly when the approval application is supposed to go in — leaving zero cushion for manufacturing scale-up, commercialization, or any trial setback. The share count has already more than doubled to 215.7 million from 100.5 million at year-end 2025 , meaning more fundraising would further dilute existing shareholders.
The Market Isn't Buying the Story — Yet. Analysts carry a consensus price target of $15.60 , more than ten times the current price — an extraordinary gap that signals either a massive opportunity or a market that sees existential risk the sell-side is ignoring. At $1.28 before this pop, the stock was trading at or below the company's cash per share. Today's rally is encouraging, but one conference presentation doesn't close the gap between promising Phase 1/2 data and a commercial product.